ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy*

Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy*
Intensive phase Continuation phase
Drugs Interval and doses
minimal duration
Drugs Interval and doses¶Δ
minimal duration
Regimen 1: Preferred regimen for HIV-infected adults with newly diagnosed tuberculosis
INH

Daily for 8 weeks

7 days per week for 56 doses (8 weeks), or

5 days per week for 40 doses (8 weeks)
INH/RIF

7 days per week for 126 doses (18 weeks), or

5 days per week for 90 doses (18 weeks)
RIF
PZA
EMB
Regimen 2: Alternative regimen for HIV-infected adults in setting of resistance or intolerance to PZA
INH

Daily for 8 weeks

7 days per week for 56 doses (8 weeks), or

5 days per week for 40 doses (8 weeks)
INH/RIF

7 days per week for 217 doses (31 weeks), or

5 days per week for 155 doses (31 weeks)
RIF
EMB
NOTE: If rifampin is replaced with rifabutin, refer to UpToDate table on rifabutin and antiretroviral therapy for dosing recommendations.

DOT: directly observed therapy; EMB: ethambutol; INH: isoniazid; PZA: pyrazinamide; RIF: rifampin.

* For HIV-infected patients who are not receiving antiretroviral therapy, the continuation phase should be extended by three months (or 90 doses) for regimen 1 (above) and for at least three months for regimen 2.[1]

¶ When DOT is used, drugs may be given five days/week, and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicated this would be an effective practice.

Δ To help evaluate treatment effectiveness, sputum smears and mycobacterial cultures should be obtained at least monthly until at least two sequential cultures are negative and the patient is responding clinically to antituberculous therapy. Patients treated with regimen 1 with positive cultures at completion of two months of therapy should receive a seven-month (31-week; 217 doses [daily]) continuation phase; those receiving regimen 2 without PZA should probably have their continuation phase extended by three months as well (one year total). Patients with a positive sputum culture after three months of therapy should be evaluated for possible treatment failure.[1]

◊ Five-day-a-week administration is always given by DOT.
Reference:
  1. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.

Data from:

  1. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America 2023. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf (Accessed on October 26, 2023).
Graphic 58653 Version 14.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟